4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 56 | 63 | +7 |
| Shares | 16.6M | 19.2M | +2.55M (+15.3%) |
| Value | $400.0M | $515.1M | +$115.0M (+28.8%) |
New holders (11)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Centiva Capital, LP | 358,863 | $7.22M | 0.58% |
| Russell Investments Group, Ltd. | 102,717 | $2.77M | 0.00% |
| Mirabella Financial Services LLP | 14,080 | $380.0K | 0.05% |
| Manufacturers Life Insurance Company, The | 11,178 | $301.0K | 0.00% |
| Goldman Sachs Group Inc | 9,686 | $261.0K | 0.00% |
| Credit Suisse AG | 8,945 | $241.0K | 0.00% |
| Voya Investment Management LLC | 8,150 | $220.0K | 0.00% |
| MetLife Investment Management | 7,979 | $215.2K | 0.00% |
| Metropolitan Life Insurance Co | 6,037 | $162.8K | 0.00% |
| Macquarie Group Ltd | 2,300 | $62.0K | 0.00% |
| UBS Group AG | 1,256 | $34.0K | 0.00% |
Sold out (4)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Jacobs Levy Equity Management, Inc | 37,417 | $901.0K |
| Walleye Capital LLC | 12,205 | $294.0K |
| Vident Investment Advisory, LLC | 8,521 | $205.0K |
| Federated Hermes, Inc. | 4,200 | $101.0K |